Centrum Alergologii Sp. z o.o.
- Address
- Ul. Wojciecha Boguslawskiego 16a, 60-214 Poznan, Poland
Immune System Diseases
Centrum Alergologii sp. z o.o. investigates immune system diseases such as allergic rhinitis and urticaria, evaluating novel immunotherapies to control inflammation and improve patient outcomes.
- Allergic rhinitis (seasonal and perennial)
- Chronic spontaneous urticaria
- Biologic agents targeting IgE
- Immune pathway modulation
Eight active studies involve four investigators at the Poznan clinic, reflecting a strong commitment to advancing treatments for immune‑mediated conditions.
Otorhinolaryngologic Diseases
Research at the centre addresses otorhinolaryngologic diseases, with a focus on birch pollen‑induced rhinoconjunctivitis and related nasal disorders, testing new allergen‑specific therapies to lessen symptom burden.
- Birch pollen‑induced allergic rhinoconjunctivitis
- Seasonal allergic rhinitis
- Pediatric allergic airway disease
- Nasal symptom relief strategies
The trials aim to demonstrate efficacy of sublingual and oral immunotherapies, providing safer alternatives to traditional antihistamines.
Respiratory Tract Diseases
The site’s program on respiratory tract diseases includes studies of Chronic Obstructive Pulmonary Disease. Researchers assess innovative inhaled combinations and monoclonal antibodies to reduce exacerbations and improve lung function.
- COPD exacerbation reduction
- Pre‑dose lung function enhancement
- Long‑acting bronchodilator combinations
- Anti‑IL‑33 therapy evaluation
These investigations support the development of therapies that can lower hospitalization rates and enhance daily breathing capacity for patients in Poland and beyond.
Skin and Connective Tissue Diseases
In the field of skin and connective tissue diseases, researchers evaluate treatments for chronic urticaria, seeking agents that quickly control hives and itching when standard antihistamines fail.
- Chronic spontaneous urticaria
- Urticaria activity score monitoring
- Comparative efficacy of new biologics
- Therapeutic equivalence studies
The work contributes to expanding options for patients who experience persistent skin eruptions, aiming for faster relief and better quality of life.
Immune System Phenomena
Beyond specific diseases, the centre explores immune system phenomena such as the underlying mechanisms of allergen sensitization and immune response modulation, guiding the design of next‑generation immunotherapies.
- Allergen‑specific immune tolerance
- Biomarker identification for treatment response
- Mechanistic studies of IgE pathways
- Immune profiling in clinical cohorts
Insights gained from these studies inform the selection of targets for the other therapeutic programs conducted at the Poznan facility.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 44 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Alergologii Sp. z o.o.
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis | Almirall S.A. | Phase III | Not Recruiting | May 2023 | Apr 2026 |
IMP list
lock Showing 1 of 44 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Formoterol Fumarate Dihydrate | 2 | Unknown | 2021-04-29 | 2022-04-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.